Single-source·Jul 17, 2026·1 sources analyzed
FDA is taking comments until July 22 before a public meeting on compounded peptides
An FDA advisory committee will meet July 23-24 on whether several peptides including BPC-157, KPV, TB-500, and MOTs-C should be allowed on the 503A bulk-substances list, with written comments due July 22 and public oral-comment slots built into the meeting.
Image: www.investors.com
Connected public decisions
Follow the issue pages where this story connects to public action.
Contact officials
Act on FDA oversight of compounded peptides
See the current decision, choose your position, and send a message through the issue page.
Take action on FDA oversight of compounded peptidesSources used · 1 source